[HTML][HTML] High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
T Watabe, M Uemura, F Soeda, S Naka, T Ujike… - Annals of Nuclear …, 2021 - Springer
Objective 18 F-labeled prostate-specific membrane antigen (PSMA) ligand, [ 18 F]PSMA-1007,
has the benefit of a higher synthetic yield and minimal excretion in the urine. High …
has the benefit of a higher synthetic yield and minimal excretion in the urine. High …
[HTML][HTML] Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG …
…, M Nakajo, M Ishibashi, H Daisaki, F Soeda… - Japanese Journal of …, 2022 - Springer
Objective In malignant melanoma patients treated with immune checkpoint inhibitor (ICI)
therapy, three different FDG-PET criteria, European Organization for Research and Treatment of …
therapy, three different FDG-PET criteria, European Organization for Research and Treatment of …
Impact of 18F-PSMA-1007 uptake in prostate cancer using different peptide concentrations: preclinical PET/CT study on mice
F Soeda, T Watabe, S Naka, Y Liu… - Journal of Nuclear …, 2019 - Soc Nuclear Med
PET radioligands with low molar activity (MA) may underestimate the quantity of the target of
interest because of competitive binding of the target with unlabeled ligand. The aim of this …
interest because of competitive binding of the target with unlabeled ligand. The aim of this …
[HTML][HTML] Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination
…, T Watabe, K Kurimoto, M Uemura, F Soeda… - EJNMMI …, 2020 - Springer
Background [ 18 F]PSMA-1007, a positron emission tomography (PET) tracer, specifically
targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate …
targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate …
[HTML][HTML] Extension of microglial activation is associated with epilepsy and cognitive dysfunction in Tuberous sclerosis complex: A TSPO-PET study
K Kagitani-Shimono, H Kato, F Soeda, Y Iwatani… - NeuroImage: Clinical, 2023 - Elsevier
Background and objectives Neuroinflammation contributes to the severity of various
neurological disorders, including epilepsy. Tuberous sclerosis complex (TSC) is a condition that …
neurological disorders, including epilepsy. Tuberous sclerosis complex (TSC) is a condition that …
[HTML][HTML] Effects of new Bayesian penalized likelihood reconstruction algorithm on visualization and quantification of upper abdominal malignant tumors in clinical FDG …
M Tatsumi, F Soeda, T Kamiya, J Ueda… - Frontiers in …, 2021 - frontiersin.org
Purpose This study evaluated the effects of new Bayesian penalized likelihood (BPL)
reconstruction algorithm on visualization and quantification of upper abdominal malignant tumors …
reconstruction algorithm on visualization and quantification of upper abdominal malignant tumors …
[HTML][HTML] Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET
M Tatsumi, F Soeda, S Naka, K Kurimoto, K Ooe… - Frontiers in …, 2022 - frontiersin.org
Purpose PET with L-4-borono-2-[ 18 F] fluoro-phenylalanine (FBPA) was reported to be useful
to differentiate malignant tumors and inflammation. Although immunotherapy with immune …
to differentiate malignant tumors and inflammation. Although immunotherapy with immune …
[HTML][HTML] Duodenal Adenocarcinoma Mimicking Metastasis of Prostate Cancer on 18F–Prostate-Specific Membrane Antigen–1007 PET/CT
F Soeda, T Watabe, H Kato, M Uemura… - Clinical Nuclear …, 2021 - journals.lww.com
A 76-year-old man with dyspnea (initial prostate-specific antigen [PSA]: 216 ng/mL) underwent
18 F-FDG PET/CT, with uptake in the prostate, lymph nodes, fifth thoracic vertebra (T5), …
18 F-FDG PET/CT, with uptake in the prostate, lymph nodes, fifth thoracic vertebra (T5), …
Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose–positron emission tomography to differentiate between benign and malignant …
M Watanabe, H Kato, D Katayama, F Soeda… - Annals of Nuclear …, 2022 - Springer
Objectives To investigate whether whole-body dynamic positron emission tomography (PET)
is useful for differentiating benign and malignant lesions. Methods In this retrospective study…
is useful for differentiating benign and malignant lesions. Methods In this retrospective study…
First in human dosimetry of 18F-NKO-035: a new PET probe targeting L-type amino acid transporter 1 (LAT1)
T Watabe, S Naka, F Soeda, T Kamiya, H Sasaki… - 2020 - Soc Nuclear Med
627 Objectives: Although 18 F-FDG is the most common PET probe in oncology, it sometimes
shows false positive uptakes in the inflammatory lesions. To overcome this disadvantage, …
shows false positive uptakes in the inflammatory lesions. To overcome this disadvantage, …